Loading
Immunic, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Nash Duane, was filed 16 Jun 2025.
Immunic, Inc.: what insiders have been doing
Immunic, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). No insider at Immunic, Inc. has published a filing in the past twelve months. The most recent one dates from 16 June 2025.
Looking back to 2016, when coverage begins, insiders filed 53 purchases and 16 sales. The 10-K for the year ended 31 December 2025 shows -97.2 m USD of net income.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
74
Thresholds
n/a
Buy Volume
€17M
53 ops. · all time
Sell Volume
€4M
16 ops. · all time
Who traded when
BuySaleJoerg Neermann2 buys
Richard Alan Rudick2 buys
Daniel Vitt1 buy
Duane Nash1 buy
Glenn Whaley1 buy
Jason Tardio1 buy
Since the insiders bought
- +84.9%Entry US$7.68 · Close at T+365 US$14.20
- +32.3%Entry US$8.85 · Close at T+365 US$11.71
- +39.1%Entry US$8.67 · Close at T+365 US$12.06
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Immunic, Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$43.09.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$6.97
Analyst consensus
11 analystsStrong buy
US$22.00Target US$43.09(+518%)US$85.00
Income statement
EBITDA-US$103.1M
Net income-US$97.2M0.0% margin
Valuation
PER (forward)-2.9x
P/Book0.7x
Beta1.45
Balance sheet & cash
Market capUS$95.1M
Total debtUS$577k
Free Cash Flow-US$86M
Debt / Equity0%
Profitability & ownership
ROE-138.2%
ROA-66.8%
% insiders1.0%
% institutions71.2%
Last declaration on 16 June 2025
Declarations74 total
20,000 shares@ US$0.834712.7% of flowCommon StockSEC:0001193805-25-000885:0
Canonical exit: 11 Sept 2025 (T+90)
12,512 shares@ US$0.79100.0% of flowCommon StockSEC:0001193805-25-000839:0
Canonical exit: 3 Sept 2025 (T+90)
15,000 shares@ US$0.7716.8% of flowCommon StockSEC:0001193805-25-000821:0
Canonical exit: 2 Sept 2025 (T+90)
30,000 shares@ US$0.7610.6% of flowCommon StockSEC:0001193805-25-000800:1
Canonical exit: 3 Sept 2025 (T+90)
70,000 shares@ US$0.7741.8% of flowCommon StockSEC:0001193805-25-000800:0
Canonical exit: 2 Sept 2025 (T+90)
45,000 shares@ US$0.712822.9% of flowCommon StockSEC:0001193805-25-000788:1
Canonical exit: 1 Sept 2025 (T+90)
25,000 shares@ US$0.5618.9% of flowCommon StockSEC:0001193805-25-000788:0
143,075 shares@ US$0.699148.3% of flowCommon StockSEC:0001193805-25-000786:0
Canonical exit: 1 Sept 2025 (T+90)
87,300 shares@ US$1.149751.7% of flowCommon StockSEC:0001193805-24-001335:0
Canonical exit: 10 Feb 2025 (T+90)
14,000 shares@ US$1.309528.1% of flowCommon StockSEC:0001193805-24-000282:0
Canonical exit: 26 May 2024 (T+90)
5,000 shares@ US$1.7512.4% of flowCommon StockSEC:0001193805-23-000735:0
Canonical exit: 13 Aug 2023 (T+90)
47,000 shares@ US$1.2629.6% of flowCommon StockSEC:0001193805-22-001729:1
Canonical exit: 14 Mar 2023 (T+90)
35,000 shares@ US$1.24636.7% of flowCommon StockSEC:0001193805-22-001729:0
Canonical exit: 13 Mar 2023 (T+90)
18,000 shares@ US$1.3921.5% of flowCommon StockSEC:0001193805-22-001609:0
Canonical exit: 21 Feb 2023 (T+90)
8,000 shares@ US$1.349917.5% of flowCommon StockSEC:0001193805-22-001602:0
Canonical exit: 20 Feb 2023 (T+90)
5,000 shares@ US$1.49511.6% of flowCommon StockSEC:0001193805-22-001497:0
Canonical exit: 5 Feb 2023 (T+90)
3,500 shares@ US$3.04515.2% of flowCommon StockSEC:0001193805-22-000918:0
Canonical exit: 1 Sept 2022 (T+90)
5,000 shares@ US$3.099923.9% of flowCommon StockSEC:0001193805-22-000919:0
Canonical exit: 1 Sept 2022 (T+90)
3,500 shares@ US$5.10100.0% of flowCommon StockSEC:0001193805-22-000800:0
Canonical exit: 10 Aug 2022 (T+90)
6,000 shares0Common StockSEC:0001193805-22-000787:1
10,000 shares@ US$5.0342.7% of flowCommon StockSEC:0001193805-22-000787:0
Canonical exit: 10 Aug 2022 (T+90)
3,000 shares@ US$5.0822.6% of flowCommon StockSEC:0001193805-22-000788:0
Canonical exit: 10 Aug 2022 (T+90)
1,000 shares@ US$9.6013.6% of flowCommon StockSEC:0001193805-21-001161:0
Canonical exit: 8 Nov 2021 (T+90)
1,000 shares@ US$9.807.4% of flowCommon StockSEC:0001193805-21-001159:0
Canonical exit: 8 Nov 2021 (T+90)
1,500 shares@ US$9.8519.4% of flowCommon StockSEC:0001193805-21-001163:0
Canonical exit: 8 Nov 2021 (T+90)
25 of 74 declarations
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a United States-listed biotechnology company traded on the NASDAQ market, focused on developing orally administered small-molecule therapies for neurologic, gastrointestinal, chronic inflammatory, and autoimmune diseases. For investors, the company should be viewed as a clinical-stage biotech with meaningful pipeline optionality, but also with the customary binary risk profile of late-stage drug development and no approved commercial product to date.
The company’s roots go back to Immunic AG, which was founded in 2016 in Planegg-Martinsried near Munich, Germany. Immunic, Inc. is the publicly listed parent vehicle and is headquartered in New York, United States, while much of its research and development activity is conducted through its German subsidiary. That transatlantic structure combines a U.S. capital markets presence with a European scientific base, which is relevant for understanding both its operating footprint and its financing strategy.
Read moreShow less
Immunic’s business model is centered on three pipeline programs. The lead asset is vidofludimus calcium (IMU-838), an orally available Nurr1 activator in Phase 3 development for relapsing multiple sclerosis (RMS). Management has stated that the ENSURE-1 and ENSURE-2 studies have completed enrollment and that top-line data are expected by the end of 2026. This asset is the key value driver for the equity and the main catalyst to watch. The company is also advancing IMU-856, designed to restore intestinal barrier function and potentially applicable across a range of gastrointestinal disorders, and IMU-381, a preclinical next-generation molecule platform aimed at neurologic, gastrointestinal, and autoimmune diseases.
Competitively, Immunic operates in a crowded and highly specialized market where large pharmaceutical companies and well-funded biotech peers compete in multiple sclerosis, neuroimmunology, and inflammatory disease. Its differentiation lies in its oral dosing profile, its mechanistic approach, and the potential to address several disease areas from a common discovery platform. At the same time, the company remains exposed to substantial clinical, regulatory, manufacturing, and financing risk, and it has not yet generated product revenue.
Recent company developments underscore both progress and capital intensity. In February 2026, Immunic announced an oversubscribed private placement of up to $200 million, with the potential for additional proceeds, aimed at funding completion of the Phase 3 ENSURE trials, initiating a Phase 3 program in primary progressive multiple sclerosis, and supporting a transition toward a commercial-stage organization. The company also reported encouraging Phase 2 CALLIPER data in progressive MS and continued to highlight patent and pipeline milestones. Overall, IMUX remains a development-stage biotechnology story with high sensitivity to clinical readouts, financing news, and execution on its lead MS program.
